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TransformationMeasurement of neutralizing antibodies to Epstein–Barr virus (EBV) is important for evaluation of candidate
vaccines. The current neutralization assay is based on antibody inhibition of EBV transformation of B cells and
requires 6 weeks to perform. We developed a rapid, quantitative ﬂow cytometry assay and show that
neutralizing antibody titers measured by the new assay strongly correlate with antibody titers in the
standard transformation-based assay. Antibodies to EBV gp350 and gp42 have been shown to block infection
of B cells by EBV. Using new assays to quantify antibodies to these glycoproteins, we show for the ﬁrst time
that human plasma contains high titers of antibody to gp42; these titers correlate with neutralization of EBV
infectivity or transformation. Furthermore, we show that antibody titers to EBV gp350 correlate more
strongly with neutralization than antibody titers to gp42. These assays should be useful in accessing antibody
responses to candidate EBV vaccines.
Published by Elsevier Inc.IntroductionEpstein–Barr virus (EBV) is a ubiquitous human herpesvirus that
usually infects childrenwho develop nonspeciﬁc symptoms or remain
asymptomatic (Cohen, 2000). Infection of adolescents or young adults
with EBV can result in infectiousmononucleosis. EBV is also associated
with several malignancies including Burkitt lymphoma, nasophar-
yngeal carcinoma, Hodgkin lymphoma, non-Hodgkin lymphoma, and
post-transplant lymphoproliferative disease. EBV infection of B cells is
initiated by interaction of its major surface glycoprotein gp350with its
cellular receptor CD21 (also known as CR2 or the C3d complement
receptor) (Fingeroth et al., 1984; Frade et al., 1985; Nemerow et al.,
1985). EBV gp42 binds to MHC class II and functions as a co-receptor
for the virus in B cells (Li et al., 1997).
Antibody to EBV gp350 can neutralize infectious virus (Hoffman
et al., 1980; Jackman et al., 1999; Miller et al., 1982; Moutschen et al.,
2007). This observation has led to the use of gp350 as a candidate
vaccine for EBV. Such vaccines have shown protection against diseasetious Diseases, Bldg. 10, Rm.
92-1888, USA. Fax: +1 301 496
osai Hospital, 3-1-69 Inabaso,
Inc.in monkeys (Epstein et al., 1985; Finerty et al., 1994; Morgan et al.,
1988a; Ragot et al., 1993), a trend toward protection from infection in
humans (Gu et al., 1995), and protection from development of
mononucleosis in humans (Sokal et al., 2007). The level of neutraliz-
ing antibody to EBV has correlated with protection from infection in
some (Finerty et al., 1992), but not all (Morgan et al., 1988b; Ragot et
al., 1993) vaccine studies in primates. The titer of neutralizing
antibody to EBV is a useful surrogate marker for evaluating EBV
vaccines. Monoclonal antibody to EBV gp42 has also been shown to
neutralize virus infection of B cells (Li et al., 1995), but antibody to
gp42 has not been demonstrated in human plasma or sera.
The conventional method to quantify neutralizing antibody tests the
ability of antibody to inhibit EBV transformation of human peripheral
blood B cells (Miller et al., 1972; Moss and Pope, 1972). This assay
requires approximately 6 weeks to perform and uses peripheral blood
mononuclear cells (PBMC) or umbilical cord blood mononuclear cells
for EBV infection. Another assay for measuring neutralization involves
the ability of antibody to inhibit Raji cell infection measured by
immunoﬂuorescent staining of the cells or counting foci of clumped
cells (Pearson et al., 1970; Rocchi and Hewetson,1973). These assays are
readmanually, are somewhat subjective, and are very labor intensive. A
competition ELISA, based on a monoclonal antibody which has
neutralizing activity, has also be used as a surrogate to estimate EBV-
neutralizing activity (Wilson andMorgan, 1998). ELISA assays have also
been used to measure antibodies to gp350 (Randle and Epstein, 1984);
Table 1
Dilution of EBV gp350 antibody 72A1 that inhibits EBV infectivity by 50% (EDI50) with
95% conﬁdence intervals.
Virus titer EBV gp350 monoclonal antibody 72A1 (gm/ml)
(GRU) EDI50 (×10−6) 95% Conﬁdence interval (×10−6)
8000 1.23 1.02–1.49
4000 1.80 1.51–2.15
2000 1.52 1.25–1.87
1000 1.56 1.30–1.87
500 1.53 1.21–1.93
Human plasma (times dilution)
EDI50 95% Conﬁdence interval
20,000 53.87 44.77–64.81
10,000 52.58 42.83–64.55
5000 58.18 46.08–73.46
2500 59.29 45.65–77.02
1250 57.09 46.56–69.99
GRU are Green Raji Units (see text).
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both neutralizing and non-neutralizing antibodies.
Recently neutralizing antibody assays have been developed using
viruses (Biacchesi et al., 2005; Bilello et al., 2006; Earl et al., 2003;
Khawplod et al., 2005) or virus particles (Pierson et al., 2006) that
express green ﬂuorescent protein (GFP). These assays are highly
quantitative, reproducible, and rapid. While these assays have been
used for other viruses, they have not been adapted to human
herpesviruses. Here we report the use of a GFP-based infection neu-
tralization assay to quantify the titer of neutralizing antibody to EBV
and use this assay to compare EBV-neutralizing titers in human
plasma to the conventional transformation neutralization assay. We
also compare the level of EBV-neutralizing antibody in human plasma
to the titer of anti-gp350 and gp42 antibodies measured by a novel
immunoprecipitation assay.
Results
Neutralization of EBV using the GFP-based infection neutralization assay
follows the percentage law
An assay that measures neutralization of EBV by sera, plasma, or
monoclonal antibody needs to be validated for certain conditions. The
percentage law, states that the titer of neutralizing antibody is notFig. 1. Neutralization of EBV B95-8/F infection by 72A1 monoclonal antibody (A) and
human plasma (B). Relative infection (percentage) was determined by dividing the
number of GFP-positive (infected) cells in the presence of antibody or plasma by the
number of GFP-positive cells in the absence of antibody or plasma and converting to
percentage for each antibody concentration (g/ml) or plasma dilution point (dilution).
Each experiment was done in triplicate and non-linear regression analysis was
performed. Symbols show the means at each point, lines show regression curves, and
shaded columns represent the range of EDI50 values in each experiment. Regardless of
the amount of virus input, measured in green Raji units [GRU], the EDI50 is constant.affected by the amount of virus present if the neutralizing antibody is
in excess over the virus (Andrewes and Elford,1933; Brioen and Boeye,
1985). While the standard neutralization assay for EBV is performed
using a ﬁxed amount of virus for each assay, it is difﬁcult to validate
that the standard assay actually follows the percentage law since theFig. 2. GFP-based infection neutralizing titration assay results for plasma samples from
EBV seropositive (A) and EBV seronegative donors (B). Non-linear regression analysis
was applied to each sample result. The dotted horizontal line in (A) is the percent of
positive cells at 50% inhibition by the plasma, and the x intercept of the vertical dotted
line is the dilution of antibody that inhibits infection by 50% (EDI50). For this plasma the
EDI50 is 101.368=23.35. Samples were deemed negative (B) if the statistical software
(Graphpad PRISM) failed to ﬁt the data to a sigmoidal regression curve. Closed circles
represent the average of triplicate values, and error bars show the range of percentage
of positive cells at each dilution point.
Fig. 3. Comparison of GFP-based infection neutralization and conventional transformation neutralization assays. (A) Effective dilution of human plasma that inhibited infectivity by
50% (EDI50) and transformation by 50% (EDT50) using the GFP infection-based and transformation-based neutralizing assay. Horizontal bars indicatemeans, vertical bars indicate 95%
CI, closed circles or squares indicate EBV seropositive plasma, and open circles or squares indicate EBV seronegative plasma. (B) Correlation between GFP-based infection and
conventional transformation neutralizing assay. Neutralization titers of 25 samples positive in both GFP-based infection and conventional transformation-based assay were plotted.
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variables. To determine how a GFP-based EBV-neutralizing assay
conforms to the percentage law, we incubated 5 serial 2-fold dilutions
of B95-8/F virus (an EBV that expresses GFP) with serial dilutions of
72A1 monoclonal antibody (which targets EBV gp350 and neutralizes
virus infectivity). The mixture was added to Raji cells and after 3 daysFig. 4. Comparison of gp350 antibody titers with GFP-based infection neutralization, convent
titers by LIPS assay for EBV seropositive (closed circles) or seronegative (open circles) human
as the mean+2 SD of blank signal (closed squares). Correlation between gp350 antibody tit
neutralization assay (C), and EBV VCA IgG ELISA (D) for human plasma samples.the cells were ﬁxed in paraformaldehyde and the number of GFP-
expressing cells was measured by ﬂow cytometry.
The percentage of GFP-positive cells, which is indicative of EBV-
infected cells, was plotted against the amount of 72A1 antibody added
(g/ml) (Fig. 1A). The effective dilution of antibody that inhibited
infectivity by 50% (EDI50), based on the reduction of GFP-positive cells,ional transformation neutralization, and VCA antibody assays. (A) Anti-gp350 antibody
plasma samples. Cut off value is shown as horizontal dotted line, which was determined
er and GFP-based infection neutralization assay (B), conventional transformation-based
252 J. Sashihara et al. / Virology 391 (2009) 249–256was calculated by regression analysis. Curves depicting the relation-
ship between infection and amount of antibody were similar over a
wide range of virus titers (Fig. 1A), and the EDI50 was nearly identical
for the different antibody titers ranging from 1.2 to 1.8×10−6 g of
antibody per ml (Table 1). Incubation of serial dilutions of B95-8/F
with serial dilutions of a human plasma, followed by infection of Raji
cells and quantiﬁcation of GFP-positive cells also yielded similar
curves (Fig. 1B) with a narrow EDI50 ranging from neutralizing
dilutions of 52.58 to 59.29 (Table 1). These results indicate that the
GFP-based EBV neutralization assay obeys the percentage law for both
a monoclonal antibody and for human plasma.
Neutralizing titers of human plasma by GFP-based assay
The GFP-based neutralizing titration assay was used to measure
EBV-neutralizing titers in 31 human plasma samples; 28 were
seropositive and 3 were seronegative by ELISA for viral capsid antigen
(VCA). B95-8/F virus was used at a titer so that 1 to 4% of Raji cells
were infected which allowed measurements that conform to the
percentage law. Serial dilutions of plasma from an EBV seropostive
donor yielded a sigmoidal curve when the number of GFP-positive
cells was plotted against the dilution of plasma, and the EDI50 was
23.35 (Fig. 2A). In contrast, plasma from an EBV seronegative donor
failed to neutralize B95-8/F (Fig. 2B). Of 29 plasma samples from EBV
seropositive donors, 28 were positive and 1 was negative for EBV-
neutralizing antibody. For the 28 positive samples the geometricmean
EDI50 was 35.13 (95% conﬁdence interval [CI], 19.88–62.06), the
median was 31.67, and the range was 1.784 to 1309 (Fig. 3A). The EBV
VCA ELISA assay in the donor that had no detectable neutralizing
antibody was 1.45 which was in the lowest quartile of the VCA titers.Fig. 5. Comparison of gp42 antibody titers with GFP-based infection neutralization, conven
titers by LIPS assay for EBV seropositive (closed circles) or seronegative (open circles) human
as the mean+2 SD of blank signal (closed squares). Correlation between gp42 antibody tite
neutralization assay (C), gp350 antibody assay, (D) and EBV VCA IgG ELISA (E) for human pThe GFP-based infection neutralization titer shows a strong correlation
with the conventional transformation neutralization assay titer using
human plasma
Of the 31 plasma samples tested by the GFP-based neutralization
assay, sufﬁcient volumes were available to test 28 samples in the
conventional neutralization assay. Of these 28 samples, 26 were from
EBV seropositive and 2 were from EBV seronegative donors. Serial
dilutions of human plasma were incubated with B95-8 EBV in 96 well
plates, PBMCs were added, and after 6 weeks the number of wells
containing transformed B cells was counted and the effective dilution of
plasma that inhibited transformation by 50% (EDT50) was calculated.
Both plasma samples from EBV seronegative donors were also negative
in the conventional transformation neutralization assay. All 26 plasma
samples fromEBV seropositive donorswere positive in the conventional
transformation neutralization assay, including the one sample which
was negative in the GFP-based infection neutralization assay. For the 26
samples positive in the transformation neutralization assay, the
geometric mean EDT50 was 42.49 (95% CI, 20.32–88.87), the median
was 22.99, and the range was 2.830 to 3158 (Fig. 3A). The one sample
that was negative in the GFP-based infection neutralization assay, but
positive in the conventional transformation neutralization assay had a
titer of 2.830, the lowest among the positive samples in this assay.
Comparison of the results of 25 samples whichwere positive in both
GFP-based infection and conventional transformation neutralizing
assays showed a highly signiﬁcant correlation between the two assays.
The Spearman's rank correlation coefﬁcient was r=0.8708 (95% CI
0.7192 to 0.9432, Pb0.0001, Fig. 3B). The neutralization titers for the 25
samples were similar in the two assays with geometric means of 41.80
(95% CI 23.80–73.42) and 47.36 (95% CI 22.75–98.60) for the GFP-basedtional transformation neutralization, and VCA antibody assays. (A) Anti-gp42 antibody
plasma samples. Cut off value is shown as horizontal dotted line, which was determined
rs and GFP-based infection neutralization assay (B), conventional transformation-based
lasma samples.
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The medians of the neutralization titers of the 25 samples were also
similar to each other (median 34.00 vs. 23.34, GFP-based infection assay
vs. conventional transformation assay, respectively).
To further compare the two assays, the GFP-based infection
neutralizing antibody titer was divided by the conventional transfor-
mation neutralizing antibody titer for each plasma sample. The me-
dian of this ratiowas 1.083, the rangewas 0.1278 to 4.361, and the 10th
and 90th percentiles were 0.2759 and 2.668, respectively. These
results indicate that these two assays provide very similar neutralizing
antibody titers.
EBV neutralization titers show a strong correlation with gp350 antibody
titers measured by a novel immunoprecipitation assay
Previously we used luciferase immunoprecipitation systems (LIPS)
assays to quantify antibody responses to a panel of herpes simplex
virus (HSV)-1 and HSV-2 antigens (Burbelo et al., 2009). In the
present study, we evaluated all 31 plasma samples using LIPS assays
for anti-gp350 EBV antibodies. This assay quantiﬁes the amount of
antibody that immunoprecipitates a gp350-Renilla luciferase fusion
protein expressed in human Cos1 cells; thus the antigen recognized by
the plasma is non-denatured gp350. All plasma samples from EBV
seropositive donors were positive in the LIPS gp350 antibody assay,
and plasma from the two EBV seronegative donors were below the
cut-off value of the LIPS gp350 assay and were therefore negative. For
the 29 plasma from EBV seropositive donors, the geometric meanwas
34,909 LU (95% CI, 22931–53144), the medianwas 36,436 LU, and the
range was 3048 to 176,217 LU (Fig. 4A).
Comparison of neutralization titers in plasma samples which were
positive by the GFP-based infection assay (28 samples) or conven-
tional transformation assay (26 samples) with the LIPS gp350
antibody assay showed a strong correlation between the three assays.
The LIPS gp350 antibody assay correlated best with the GFP-based
infection neutralization assay showing a Spearman's r value of 0.8550
(95% CI, 0.7017 to 0.9326, Pb0.0001) (Fig. 4B); the LIPS gp350 anti-
body assay also showed a strong correlation with the conventional
transformation neutralization assay with r=0.7559 (95% CI 0.5122 to
0.8869), Pb0.0001 (Fig. 4C).
Comparison of the LIPS gp350 antibodyassaywith the VCA IgG ELISA
assay showed a less robust correlation than with the neutralization
assays with r=0.4839 (95% CI 0.1237 to 0.7314), P=0.0091 (Fig. 4D).
We tested 14 additional coded plasma for antibody to gp350 and in
the GFP-based neutralization assay. All 6 EBV seronegative plasma
(based on VCA IgG ELISA) obtained from adults were negative in both
the gp350 antibody and in the GFP-based neutralization assay. All 3
EBV seropositive plasma from adults were positive in both gp350 and
the neutralization assay. Of 5 seropositive plasma from umbilical cord
bloods, all were seropositive in the gp350 antibody assay and 3 of 5
were positive in the GFP-based neutralization assay. Thus, the gp350
antibody assay correlated well with the VCA ELISA assay for both
seropositive and seronegative samples.
EBV neutralization titers show a less robust correlation with gp42
antibody titers than to gp350 antibody titers
Similar to the results observed for the gp350 antibody titers, all 29
plasma samples from EBV seropositive donors were positive in the
LIPS gp42 antibody assay, while plasma from 2 seronegative donors
were below the cut-off value of the LIPS gp42 assay. The geometric
mean, median and range of the 29 plasma from EBV seropositive
donors were 162334 LU (95% CI; 116710 to 225793 LU), 181750 LU,
25989 to 655407 LU, respectively (Fig. 5A). Moderate correlations
were shown between LIPS gp42 antibody titers and the GFP-based
infection neutralizing assay (r=0.6700, Pb0.0001), the conventional
transformation neutralizing assay (r=0.5405, P=0.0044), LIPSgp350 antibody titers (r=0.6103, P=0.0004), and the VCA IgG
ELISA assay (r=0.4275, P=0.0233) (Figs. 5B–E).
Discussion
We have shown that a GFP-based EBV infection neutralization
assay compares favorably with the conventional transformation-
based neutralization assay. In addition we ﬁnd that human plasma
contains high titers of antibody to gp42 that correlate with neutra-
lization of EBV infectivity or transformation; however antibody titers
to EBV gp350 correlate more strongly with neutralization than anti-
body titers to gp42.
Quantiﬁcation of EBV-neutralizing antibody titers in humans is
important for evaluation of candidate EBV vaccines. Conventional assays
that measure antibodies which neutralize B cell transformation by EBV
are very cumbersome and require lengthy periods of time (usually
6 weeks) to obtain results. Human PBMCs or cord blood mononuclear
cellsmust be used; the latter are not readily available. These cellsmay be
infected with adventitious agents and require precautions when
working with uncharacterized human specimens. PBMCs vary in their
susceptibility to infection and transformation. B95-8 cells, which were
derived from cottontop tamarins – an endangered species – cannot be
commercially distributed. Speciﬁc aspects of the assay, particularly the
variation in human cells from donor to donor, differences in fetal bovine
serum, and differences in handling the cultures during the 6 weeks
required for the assaymay result in variationwhen results are compared
among different laboratories.
The GFP-based infection neutralizing titration assay we report here
has a number of advantages that circumvent the problems associated
with the transformation assay. The GFP assay requires only 3 to 4 days
and uses an established cell line – Raji – rather than heterogeneous
populations of primary human cells. This assay is not highly depen-
dent on the concentration of virus used since it conforms to the
percentage law. These properties should result in less variation when
performed over different times and between different laboratories.
The ease in performing the assay and the shorter time period allows
multiple replicates to be performed. We found that the neutralizing
titers obtained by the GFP-based infection assay had a strong
correlation with the conventional transformation assay. Thus, the
GFP-based assay is a useful alternative to the conventional, transfor-
mation-based assay for measuring neutralizing antibody.
Borza and Hutt-Fletcher (2002) reported that EBV derived from
epithelial cells infects B cells more efﬁciently than epithelial cells,
while EBV derived from B cells infects epithelial cells more effectively.
The virus used in our GFP-based assay, B95-8/F, is grown in 293/2089
human epithelial cells, while the virus used in the conventional assay,
B95-8, is propagated in cotton top tamarin B cells. Since EBV is thought
to be transmitted from saliva, which contains virus derived from
lytically infected epithelial cells (Jiang et al., 2006), neutralization of
virus produced in human epithelial cells may be more appropriate
than virus produced in monkey B cells.
We found that the GFP-based infection neutralization assay
conforms with the percentage law, which indicates that the titer of
neutralizing antibody is independent of the quantity of virus (or viral
antigen) if antibody is in excess relative to the amount of virus at
informative points on the sigmoidal neutralization curve (Andrewes
and Elford, 1933). Since the B95-8/F virus is derived by transfecting
cells with a plasmid expressing BALF4 (glycoprotein 110 or gB), there
were concerns that excessive amounts of gp110, which is required for
virus fusion with B cells, in the virus preparation could interfere with
the neutralization assay. Similar concerns with soluble antigens or
defective virus particles have been raised with other neutralization
assays (Pierson et al., 2006). As we showed in this study, the EBV GFP-
based neutralization assay obeyed the percentage law over a wide
range of virus titers; therefore additional gp110 generated from the
transfection did not interfere with the assay.
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herpesviruses and both glycoproteins are important for virus infection.
EBV gp350 is expressed in the virus envelope and on virus-infected cells
(Beisel et al., 1985; Johannsen et al., 2004), and antibody to gp350 is
known to neutralize virus infectivity (Hoffman et al., 1980; Jackman
et al., 1999; Miller et al., 1982; Moutschen et al., 2007). EBV gp350 is
important for attachment to cells (Tanner et al.,1987).We found that the
level of antibody to gp350 based on the LIPS assay showed a strong
correlation to both the GFP-based and transformation-based neutrali-
zing antibody titers (r=0.8550 and 0.7559, respectively, Pb0.0001).
The LIPS assay measures antibodies that immunoprecipitate gp350
expressed in human cells in non-denaturing conditions.Many assays for
gp350 antibodies are ELISA-based and rely on antibody binding to small
peptides bound to a plastic well (Randle and Epstein, 1984). A previous
study showed that EBV-neutralizing antibodies recognize conforma-
tion-dependent epitopes (Zhang and Marcus-Sekura, 1993). Therefore
antibodies that detect gp350 using synthetic peptides on a plate by
ELISA may be less likely to correlate with neutralizing titers than
antibodies that recognize gp350 protein expressed in mammalian cells
by immunoprecipitation in the LIPS assay.
EBV gp42 is present on the surface of infected cells and in the
virion envelope (Johannsen et al., 2004). EBV gp42 is important
for fusion of virus with the cell (Kirschner et al., 2007; Miller and
Hutt-Fletcher, 1988). EBV produced in epithelial cells contains higher
levels of gp42 than EBV made in B cells, and the former virus infects B
cells more efﬁciently than the latter (Borza and Hutt-Fletcher, 2002).
Thus, the amount of gp42 in EBV may determine tropism of the virus
for different types of cells. Antibody to gp42 can neutralize EBV
infectivity of B cells (Li et al., 1995) and virus lacking gp42 is unable to
infect B cells (Wang and Hutt-Fletcher, 1998).
We found while that antibody titers to gp42 based on the LIPS
assay correlated with neutralization of virus by the conventional
transformation and the infection GFP-based assays, the correlation
with the neutralization assays was less robust than for that observed
with the gp350 antibody assay. These results suggest that antibody to
EBV gp350 may be a more important contributor to EBV-neutralizing
activity in human plasma than antibody to gp42. Nevertheless anti-
bodies produced to glycoproteins that are important for different
stages of infectivity, attachment (gp350) and fusion (gp42), both
correlate with neutralization of infectivity.
The neutralization titers measured by the GFP assay measure the
ability of antibody to prevent infection of B cells, while the
conventional neutralization assay with B95-8 virus measures anti-
bodies that inhibit EBV-induced transformation. EBV has a very high
transformation efﬁciency and can transform 3 to 10% of B cells in
culture (Henderson et al., 1977; Sugden and Mark, 1977). Thus, while
these assays measure somewhat different properties of the virus, the
efﬁciency of EBV transformation likely explains the strong correlation
of the results of the two assays.
In summary, we report the development of two novel assays whose
activities correlate well with the conventional transformation-based
neutralizing assay. While the LIPS assay for gp350 does not distinguish
between neutralizing and non-neutralizing antibodies, it can be done
rapidly, has awidedynamic range, and the results fromthe assaystrongly
correlated with the conventional neutralizing assay. The GFP-based
infection neutralization assay is highly quantitative and easy to perform.
This assaymay ultimately replace themore cumbersome transformation
neutralization assay and obviate the need to obtain primary human
mononuclear cells and to wait several weeks for the results.
Materials and methods
Cells
B95-8 cells (an EBV-transformed cotton top tamarin cell line), Raji
cells (an EBV-positive human Burkitt lymphoma cell line), and HB168cells (a mouse hybridoma that expresses anti-gp350 neutralizing
antibody (American Type Culture Collection, Manassas, VA) were
propagated in culture media (RPMI 1640 with 10% fetal bovine serum
[FBS], 100 U/mL penicillin, 100 μg/mL streptomycin and 2 mM L-
glutamine). 293/2089 cells (Delecluse et al., 1998), which contain the
B95-8/F virus genome, were kindly provided by Henri-Jacques
Delecluse and Bill Sugden and were cultured in DMEM with 10%
FBS, L-glutamine, penicillin, streptomycin, and 50 μM hygromycin.
Blood was obtained from healthy donors at the Warren G.
Magnuson Clinical Center at the National Institutes of Health under
an Institutional Review Board approved protocol and PBMCs were
isolated from buffy coat preparations using Ficoll-Paque Plus (GE
Healthcare Bio-Sciences AB, Uppsala, Sweden). EBV-infected B cells
were propagated in transformation media (IMDM with Glutamax
[Invitrogen, Carlsbad, CA] in 20% fetal bovine serum, L-glutamine,
penicillin, and streptomycin). Plasma was obtained from blood bank
donors at the National Institutes of Health and from healthy donors at
the Center for Cell and Gene Therapy, Baylor College of Medicine
under protocols approved by Institutional Review Boards at both
institutions.
Viruses and virus titrations
EBV B95-8 was obtained from B95-8 cells after incubation with
20 ng/mL 12-O-tetradecanoyl-phorbol-13-acetate and 3 mM butyric
acid (Sigma-Aldrich, St. Louis,MO).After72h, the cellswere collectedby
centrifugation (300×g), the supernatantwas transferred to 4 °C, and the
cell pellet was frozen and thawed 3 times, added back to the super-
natant, and themixturewas centrifuged at 300×g. The supernatantwas
passed through a 0.45 μm MCE membrane ﬁlter (Millipore, Billerica,
MA) and then underwent ultracentrifugation at 10,000 ×g for 1 h. The
pellet was resuspended in RPMIwith 10% FBS and the concentrated EBV
B95-8 virus stock was stored at−70 °C until use.
B95-8/F virus, which expresses GFP, was prepared from 293/2089
cells (Delecluse et al., 1998). 293/2089 cells were transfected with
plasmids p509 and p2670 expressing EBV BZLF1 and EBV BALF4
(Neuhierl et al., 2002), respectively, using Lipofectamine 2000 (Invitro-
gen). At 72 h after transfection, medium was collected and passed
through a 0.80 μm MCE membrane ﬁlter, and the B95-8/F virus stock
was stored at 4 °C for several weeks or−70 °C for long term storage.
To titrate B95-8 virus, 10-fold serial dilutions of virus (beginning at
50 μl of undiluted virus) were incubated with 50 μl of 1×105 PBMCs in
each well of a round bottom 96-well plate at 37 °C for 1 h. Each
dilution of virus was done in 6 replicates. The plates were centrifuged
at 300 ×g for 5 min, the media was removed, and transformation
medium containing 0.5 μg/mL of cyclosporine A was added. After
1 week, 50 μl of media containing 0.5 μg/ml cyclosporine Awas added,
and after 3 and 5 weeks media was added without cyclosporine A. The
number of wells containing transformed B cells was determined at
week 6 and the tissue culture transforming dose that resulted in
transformants in 50% of the wells (TCTD50) was calculated using the
method of Reed and Muench (1938).
To titrate B95-8/F virus, 25 μl of virus stock was incubated with
75 μl of 1×105 Raji cells for 1 h in each well of a 96 well round bottom
plate. The cells were then washed twice by centrifuging the plates at
300 ×g for 5 min, and replacing the media with 100 μl of fresh culture
media and then culturing the cells at 37 °C. After 3 days the proportion
of GFP-positive cells was measured by ﬂow cytometry. The following
equation was used as a starting point for estimating infected cells:
GreenRaji Unit ðGRU=mlÞ = number of GFP1positive cells
= total number of Raji cells
× total numbers of cells
× dilution factor:
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follows a Poisson distribution, so that the probability that a well has a
least one positive cell is 1−ea where e is the base of the natural
logarithm and a is the parameter for the Poisson distribution. This
Poisson distribution assumption has been used previously for calculat-
ing the number of herpesvirus genomes in infected cells (Hoshino et al.,
2008). An estimate of a is obtained by equating the number of GFP-
positive cells (G)/total number of Raji cells (n) to 1−ea. Solving this
equation for a results in a=− ln(1−G/n). Therefore we revised the
original equation for Green Raji Units and calculated the number of
EBV-infected cells using the following equation:
GreenRaji Unit ðGRUÞ=ml = − lnð1−½numberof GFPpositive cells
= total number of Raji cellsÞ
× total number of cells
× dilution factor:
The dilution factor in the equation above was 1000/25 since 25 μl of
virus was placed in a well and the number of Green Raji units are
expressed per ml (1000 μl). Each well contained 105 cells in a total
volume of 100 μl. Each titration was performed in 3 to 6 replicates.
EBV-neutralizing monoclonal antibody, ELISA assay, and human plasma
EBV-neutralizing monoclonal antibody 72A1 was obtained from
the media of B168 cells and puriﬁed by protein G column
chromatography and resuspended in 2× PBS. Human plasma samples
were heat-inactivated at 56 °C for 30 min to inactivate complement
and clotting factors and then tested for anti-EBV VCA IgG and anti-EBV
nuclear antigen (recombinant EBNA-1) IgG by ELISA (Bio-Rad
Laboratories, Hercules, CA).
Of 31 plasma samples, 26 were positive for anti-VCA IgG, 2 were
weakly positive and 3 were negative. Of the 31 plasma samples, 21
were positive for anti-EBNA IgG, 2 were weakly positive, 7 were
negative and 1 was not tested because of limited amounts of plasma.
Of 5 samples which hadweakly positive or negative results in the anti-
VCA assay, 3 were positive for anti-EBNA and only 2 samples were
negative in both the anti-VCA and anti-EBNA assays. Thus 29 plasma
were deﬁned as EBV seropositive (EBV VCA IgG and/or EBNA IgG
positive), and two were deemed seronegative (EBV VCA and EBNA
IgG negative). These samples were subsequently tested for EBV-
neutralizing activity, gp350, and gp42 antibody titers. An additional 14
coded human serum samples were tested in the neutralization, gp350,
gp42, and VCA IgG ELISA antibody assays.
Luciferase immunoprecipitation system (LIPS) assay
A fusion protein containing the EBV gp350 gene linked to the Re-
nilla luciferase gene was constructed in the mammalian expression
vector pREN3S. The extracellular domain of EBV gp350, including the
ﬁrst methionine codon, from B95-8 viral DNA was ampliﬁed by PCR
using forward primer 5′-AAAAGATCTACCATGGAGGCAGCCTT-
GCTTGTGTGTC-3′ and reverse primer 5′-AAAAGATCTGGAGGTTTGA-
GAATCTGGGCTGGGACGT-3′. The PCR product was digested with BglII
and cloned into the corresponding BglII site of pREN3S. The resulting
plasmid contains the extracellular domain of EBV gp350 with a
carboxyl terminal Renilla luciferase gene. An EBV gp42–Renilla
luciferase gene fusion protein was constructed by PCR ampliﬁcation
of the full-length EBV gp42 open reading frame using forward primer
5′-GAGAGATCTGTTTCATTTAAGCAGGTG-3′ and reverse primer 5′-
GAGCTCGAGTTAGCTATTTGATCTTTGAC-3′. The PCR product was
digested with BglII and XhoI and cloned into the BamHI and XhoI
sites of pREN2 (Burbelo et al., 2005). The resulting plasmid contains
full-length EBV gp42 with an amino terminal Renilla luciferase gene.
Since gp42 is normally cleaved at its amino terminus around residue40 (Ressing et al., 2005) and there was concern that the amino
terminal Renilla luciferase moiety could be cleaved off, we veriﬁed
that the construct remained intact by immunoprecipitation with
human serum or monoclonal antibody to gp42. The gp42 monoclonal
antibody pulled down even more of the Renilla luciferase–gp42
protein than did EBV-positive human serum, conﬁrming that the
Renilla luciferase–gp42 construct remained intact (data not shown).
The EBV inserts in both the Renilla luciferase gp42 and gp350
constructs were conﬁrmed by sequence analysis.
Cos1 cells were transfectedwith plasmids containing EBV gp350 or
gp42 Renilla luciferase fusion proteins and activity of lysates was
determined by measuring light units (LU) using a luminometer as
described previously (Burbelo et al., 2009). Human plasma or sera
were diluted 1:10 and 10 μl was added to 1×107 light units (LU) of
transfected Cos1 cell extract, immunoprecipitations were performed
with addition of protein A/G beads, and LU were determined by a
plate luminometer. A cut-off threshold limit was derived from the
mean value plus 2 standard deviations of background LU. All LU data
shown represent the average of two independent experiments.
Conventional EBV transformation neutralizing titration assay
25 μl of undiluted and 2-fold serial dilutions of human plasma or
sera were incubated with 25 μl of 10 TCID50 of EBV B95-8 in round
bottom wells of a 96 well plate at 37 °C for 2 h. 50 μl of 1×105 PBMC
was added for 1 h and the plates were then centrifuged at 300 ×g for
5 min, the media was removed, and transformation media containing
0.5 μg/mL of cyclosporine A was added. After 1 week 50 μl of media
containing 0.5 μg/ml cyclosporine A was added, and after 3 and
5 weeks 50 μL of transformation media was added without
cyclosporine A. Each assay was performed in 6 replicates. The number
of transformed wells was determined at week 6 and the effective
dilution of plasma that inhibited transformation by 50% (EDT50) was
calculated based on the method of Reed and Muench (1938).
GFP-based EBV infection neutralizing titration assay
Human sera, human plasma, media, or 72A1 monoclonal antibody
was serially diluted in 2-fold steps (fromundiluted to 18 serial dilutions)
and 25 μL of the diluted antibodywas added towells of a 96well plate in
triplicate. 25 μl of B95-8/F virus was added to each well and incubated
for 2 h. 50 μl of 1×105 Raji cells were added and incubated for 1 h at
37 °C, the cells were washed twice by centrifuging the plates at 300 ×g
for 5min and replacing themedia, and incubated for 3 days at 37 °C. The
platewas then centrifuged, the cellswerewashedoncewithPBS, thePBS
was removed, and the cells were ﬁxed in 2% paraformaldehyde in PBS.
GFP-expressing cells were quantiﬁed using a FACSCalibur Flow
Cytometer (BD Biosciences, San Jose, CA, USA) and FlowJo software
(Tree Star Inc., Ashland, OR). The effective dilution of antibody that
inhibited infectivity by 50% (EDI50) based on reduction of the number
of GFP-positive cells was calculated by non-linear regression analysis
using GraphPad PRISM software. Neutralizing antibody was consid-
ered absent when the software program failed to ﬁt the results to an
appropriate regression curve.
Statistical analyses
Correlations between GFP-based neutralization assay, conven-
tional neutralizing assay, gp350 antibody, gp42 antibody titers, and
VCA IgG ELISA were evaluated by Spearman's rank test using
GraphPad PRISM Software (San Diego, CA).
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